Introduction {#s1}
============

Lytic transglycosylases (LTs) degrade peptidoglycan (PG) to produce *N*-acetylglucosamine (GlcNAc)−1,6-anhydro-*N*-acetylmuramic acid (MurNAc)-peptide (G-anhM-peptide), a key cytotoxic elicitor of harmful innate immune responses ([@bib54]). LTs have been classified into four distinct families based on sequence similarities and consensus sequences. LTs belonging to family 1 of the glycoside hydrolase (GH) family 23 share sequence similarity with the goose-type lysozyme ([@bib6]). Family 1 can be further subdivided into five subfamilies, 1A through E, which are all structurally distinct ([@bib6]). Despite the overall structural differences among LTs, their active sites, enzymatic activities and substrate specificities are fairly well conserved.

The crystal structure of the outer membrane lipoprotein LtgA, a homolog of Slt70 that belongs to family 1A of GH family 23 from the pathogenic *Neisseria* species, was previously determined at a resolution of 1.4 Å ([Figure 1a](#fig1){ref-type="fig"}). ([@bib63]; [@bib64]). Briefly, LtgA is a highly alpha-superhelical structure consisting of 37 alpha helices ([Figure 1a](#fig1){ref-type="fig"}). Although LTs have very diverse overall secondary structures, they exhibit similar substrate specificities and a preference for PG ([@bib55]). LtgA shares an overall weak sequence similarity with Slt70 (25%). However, the structural and sequence alignments of the catalytic domains of Slt70 and LtgA revealed absolute active site conservation ([@bib64]). The active site of LtgA is formed by ten alpha helices (α 28, 29, 30, 31, 32, 33, 34, 35, 36, 37), with a six-alphahelix bundle (α 29, 30, 31, 32, 33, 34) constituting the core of the active site that firmly secures the glycan chain ([Figure 1a](#fig1){ref-type="fig"}).

![Molecular architecture of LtgA alpha helix 30 and contacts made with reaction.\
intermediates. (**a**) Native structure of LtgA. Ribbon model of LtgA displaying a helical structure consisting of 37 alpha helices. LtgA consists of three domains: A C-domain (gray and red), which houses the putative catalytic domain, and the L (yellow) and U (green) domains, which are of unknown function. A long N-terminal extension interacts with the L-domain, which closes the structure (PDB ID: 5O29). Clear and consistent density for helix 30 was depicted by the Fo-Fc omit map (green) (**b**) LtgA with a disordered conformation of helix 30. Clear and consistent density for helix 30 was absent as depicted by the Fo-Fc omit map (green) of helix 30 (PDB ID: 6H5F). (**c**) LtgA plus trapped intermediates (chitotetraose and a GlcNAc sugar) (PDB ID: 5O2N). (**d**) LtgA plus anhydro product (1,6-anhydro-chitotriose) (PDB ID: 5OIJ).](elife-51247-fig1){#fig1}

LTs utilize a single catalytic residue, either a glutamate or aspartate, which plays the role of an acid and then that of a base ([@bib48]; [@bib50]; [@bib38]; [@bib33]; [@bib51]). In our recent study, active LtgA was monitored for the first time in the crystalline state, and the residues involved in the substrate and product formation steps were identified. Globally, conformational changes occurred in three domains, the U, C and L domains, between native LtgA and LtgA bound to the product ([@bib64]). Substantial conformational changes were observed in the active site, for example, during the product formation step, the active site adopted a more open conformation ([@bib64]).

Many Gram-negative bacteria have multiple and redundant LTs; for example, *Escherichia coli* has eight (MltA, MltB, MltC, MltD, MltE, MltF, MltG and Slt70), and *Neisseria* species encode 5 (LtgA, LtgB, LtgC, LtgD, and LtgE). Because the activity of LTs is redundant, the loss of one or more LTs in *E. coli* leads to no observable growth defects. When genes for six LTs were deleted from *E. coli*, a mild chaining phenotype was observed ([@bib22]). However, despite lack of strong observable phenotypic changes, it has been suggested that LTs may have well-defined roles in the cell. For example, the deletion of *ltgA* and *ltgD* in *Neisseria gonorrhoeae* eliminates the release of cytotoxic PG monomers suggesting the activities of LtgA and LtgD are redundant. Moreover, LtgA primarily localizes at the septum, indicating a role in the divisome machinery, whereas LtgD is distributed along the entire cell surface ([@bib37]).

The activities of LTs are known to be inhibited by β-hexosaminidase inhibitors (for example, NAG-thiazoline); by bulgecins A, B and C; and by PG-*O*-acetylation ([@bib63]; [@bib33]; [@bib46]; [@bib49]). PG-*O*-acetylation ([@bib58]) is a process that allows pathogenic bacteria to subvert the host innate immune response ([@bib15]; [@bib4]). It should be noted that many Gram-positive and [Gram-negative bacteria](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/gram-negative-bacterium) *O*-acetylate their PG, with a few notable exceptions such as *E. coli* and *Pseudomonas aeruginosa* ([@bib10]). Peptidoglycan *O*-acetylation prevents the normal metabolism and maturation of [PG](http://goldbook.iupac.org/P04480.html) by LTs ([@bib5]). Ape1, a PG de *O*-acetylase, is present in *Neisseria* species and generally in Gram-negative bacteria that *O*-acetylate their PG. Ape1 catalyzes the hydrolysis of the *O*-acetyl modification specifically at the sixth carbon position of the muramoyl residue, thus assuring the normal metabolism of PG by LTs ([@bib58]; [@bib59]; [@bib32]).

LTs form protein complexes with other members of the PG biosynthetic apparatus, such as PBPs ([@bib55]; [@bib16]; [@bib34]; [@bib52]; [@bib28]; [@bib56]). Most notable are the interactions between Slt70 and PBPs 1b, 1c, 2 and 3 ([@bib57]). PBPs are essential for bacterial cell wall synthesis and are required for proliferation, cell division and the maintenance of the bacterial cell structure. Previously, PBPs were thought to be primarily responsible for the polymerization of PG. Recently, RodA, a key member of the elongasome, and a shape, elongation, division and sporulation (SEDS) protein family member was shown to be a PG polymerase. RodA functions together with PBP2 to replicate the transglycosylase and transpeptidase activities found in bifunctional PBPs ([@bib9]; [@bib29]; [@bib41]). SEDS proteins are widely distributed in bacteria and are important in both the cell elongation and division machinery. *Neisseria* species such as *N. gonorrhoeae* and *N. meningitidis* are coccoid in shape and lack an elongation machinery. Therefore, these species incorporate new PG through complex interactions in the divisome. Both *N. gonorrhoeae* and *N. meningitidis* have five PBPs, namely, PBP1, PBP2, PBP3, PBP4 and PBP5. PBP1 and PBP2 are homologous to *E. coli* PBP1a and PBP3, while the *Neisseria* PBP3 and PBP4 are homologous to *E. coli* PBP4 and PBP7 ([@bib36]). PBP5 in both *E. coli* and *Neisseria* species are both predicted carboxypeptidases ([@bib65]). FtsW, a RodA homolog and a key component of the divisome machinery, forms a complex with FtsI (PBP3). The FtsW-PBP3 complex shares similar interacting regions with the RodA-PBP2 complex, and is the confirmed PG polymerase of the divisome ([@bib44]).

Previous work by our group and others have demonstrated that PBPs and LTs can be targeted in a combined antibiotic regimen that could counter antibiotic resistance ([@bib7]), highlighting the possibility of simultaneously inhibiting LTs and their binding partners, such as PBPs, to achieve a synergistic antibiotic effect. Here, we reveal the near-atomic-resolution crystal structure of a native version of LtgA with a disordered active site alpha helix. When LtgA, missing the alpha helix 30 motif, was expressed from an ectopic locus in *N. meningitidis* (at an elevated level compared to wild type), bacterial growth, cell division and daughter cell separation were disrupted, compromising the integrity of the cell wall and PG composition, and diminishing bacterial fitness or virulence in a mouse infection model. It is known that LTs exist in multi-protein complexes. Here, we demonstrate that LTs can enhance the activity of one of their protein-binding partners thus ascribing a new role to LTs in the PG degrading machinery. This study demonstrates that despite the redundancy of LTs, they can be useful potential targets for future antibiotic development.

Results {#s2}
=======

Structure of LtgA with a disordered alpha helix 30 {#s2-1}
--------------------------------------------------

In the course of monitoring the LtgA reaction in the crystalline state, we captured a native version of LtgA with a distinctly disordered alpha helix 30 ([Figure 1a--b](#fig1){ref-type="fig"}, [Video 1](#video1){ref-type="video"}). This represents a newly identified conformational state of LtgA whereby alpha helix 30 transitions from an ordered to a disordered state ([Figure 1a--b](#fig1){ref-type="fig"}). Interestingly, this disorder of alpha helix 30 did not affect the overall structural integrity of the active site ([Figure 1b](#fig1){ref-type="fig"}, [Video 1](#video1){ref-type="video"}) because all the other helices making up the catalytic domain remained intact. Moreover, LtgA was already shown to be active in the crystalline state in our previous studies, although the molecular details of alpha helix 30 interactions with the ligand was not addressed ([Figure 1a--b](#fig1){ref-type="fig"}, [Video 1](#video1){ref-type="video"}; [@bib64]).

###### Video of LtgA cleaving a glycan strand.

Alpha helix 30, with the sequence ^501^(MPATAREIAGKIGMD)^516^ ([Figure 1a--b](#fig1){ref-type="fig"}, colored in light red), is structurally conserved among the closest homologs of LtgA, mainly, Slt's, and other LTs such as MltE and MltC ([@bib50]; [@bib2]; [@bib18]; [@bib3]; [@bib23]; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Alpha helix 30 clamps the glycan strand during catalysis ([Figure 1c](#fig1){ref-type="fig"}, [Video 1](#video1){ref-type="video"}) and undergoes conformational changes to a more open conformation after product formation ([Figure 1d](#fig1){ref-type="fig"}). Met 501 and Glu 507 of alpha helix 30 lose hydrogen-bonding contact with the ligand after product formation ([Figure 1d](#fig1){ref-type="fig"}, [Video 1](#video1){ref-type="video"}). Consistent with the structural data showing the role of alpha helix 30 in substrate/product binding, a heterologously expressed and purified LtgA^Δ30^ showed severely diminished PG-binding capabilities when compared to wild-type LtgA or mutants of residues involved in the catalytic mechanism or substrate binding (E481A, E580) of LtgA ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). This further emphasizes the potential critical structural role of alpha helix 30 in the function of LtgA and consequently in the proper metabolism of the PG.

The functional role of alpha helix 30 {#s2-2}
-------------------------------------

Given the important structural role of LtgA alpha helix 30, we investigated its functional role in vivo by engineering the following constructs in *N. meningitidis*: i) an LtgA knockout strain (Δ*ltgA*), ii) a knockout strain complemented at an ectopic locus on the meningococcal chromosome with the wild-type gene (Δ*ltgA^ltgA^*), or iii) complemented with alpha helix 30 deletion (Δ*ltgA^ltgA^*^Δ30^). Similar to other LTs, a complete deletion of the *ltgA* gene from the chromosome did not affect the growth of the bacteria ([Figure 2a](#fig2){ref-type="fig"}; [@bib8]). Interestingly, the strain with *ltgA* lacking the alpha helix 30 coding sequence exhibited severely reduced growth ([Figure 2a](#fig2){ref-type="fig"}), with an exponential phase growth rate (0.059 h^−1^ ±0.012) significantly different from that of the wild-type or Δ*ltgA^ltgA^* strain (0.72 h^−1^ ±0.15 or 0.21 h^−1^ ±0.043, respectively) based on the calculated slopes of the growth curves (p\<0.0001) ([Figure 2a](#fig2){ref-type="fig"}).

![The LtgA helix 30 mutant leads to a growth defect and is stable.\
(**a**) Growth kinetics of *N. meningitidis* wild-type, *ΔltgA*, *ΔltgA^ltgA^* and *ΔltgA^ltgA^*^Δ30^ strains. Data represent three independent experiments. (**b**) Exponentially grown bacteria were treated with chloramphenicol (2 μg/ml) to block protein synthesis and survey the stability of LtgA for the indicated periods of time (in hours). Immunoblots were performed probing with anti-LtgA antibody. The expression of the outer membrane protein fHbp was used as an loading control. (**c**) The levels of LtgA over the time were analyzed and plotted as a stability curve by quantifying the band intensities using ImageJ software. For each strain, the LtgA intensity at time zero is referred to as 100%, while the simultaneously fHbp was used for loading control.\
Figure 2---source data 1.[Figure 2a](#fig2){ref-type="fig"} -- Analysis associated with growth kinetics of N. meningitidis wild-type, ΔltgA, ΔltgA ^ltgA^ and ΔltgA ^ltgAΔ30^ strains.\
Figure 2---source data 2.[Figure 2c](#fig2){ref-type="fig"} -- The stability of LtgA over time.](elife-51247-fig2){#fig2}

To exclude concerns about LtgA stability and to confirm that LtgA^Δ30^ continued to be expressed, the degradation of LtgA across all four strains was examined by western blot of lysates of bacteria harvested at various time points after incubation with chloramphenicol ([Figure 2b--c](#fig2){ref-type="fig"}). As expected, LtgA was not detected in the Δ*ltgA* knockout mutant ([Figure 2b--c](#fig2){ref-type="fig"}). The levels of LtgA or LtgA ^Δ30^ in the Δ*ltgA^ltgA^* and Δ*ltgA^ltgA^*^Δ30^ strains was 4.2 and 3.7 times higher, respectively, than observed in the wild-type strain at t~0~, possibly because the transcription of *ltgA* was controlled by a stronger promoter in these strains when compared to the parental strain. After the addition of chloramphenicol, LtgA appeared to be maintained at comparable levels in the wild-type and complemented strains, and the levels decreased slowly during the sampling period, as revealed by quantitative measurement of relative protein abundance using densitometry (*t*~1/2~ \> 9 h) ([Figure 2b--c](#fig2){ref-type="fig"}).

The promoter for *ltgA* has not yet been identified; therefore, *ltgA* was introduced in the chromosome of meningococcus and expressed under the control of a non-native promoter. Since Δ*ltgA^ltgA^*^Δ30^ exhibited reduced growth and this could be attributed to bacterial lysis or defects in cell division or cell separation, we examined all four strains using fluorescent microscopy (labeling the membrane and intracellular DNA), and scanning electron microscopy (SEM). Despite the reduced growth of strain Δ*ltgA^ltgA^*^Δ30^, there was no physical evidence suggesting bacterial lysis. However, intriguingly in the Δ*ltgA^ltgA^*^Δ30^ strain, we observedstrong defects in cell separation and cell division, and the appearance of membrane stained extracellular material that was notably absent in the other three strains ([Figure 3](#fig3){ref-type="fig"} (*right panel*), [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Additionally, SEM revealed large blebs on the surface of some of the unseparated/undivided bacteria in the Δ*ltgA^ltgA^*^Δ30^ strain that were not observed in the other strains. A rather striking phenomenon is that the bacteria with blebs all had smooth surfaces that deviated from the normal rough surface appearance of *N. meningitidis* in the other strains ([Figure 3](#fig3){ref-type="fig"} (*left panel*), [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We also observed ghost cells; however, this phenomenon was not as pervasive as other abnormalities ([Figure 3](#fig3){ref-type="fig"} (*left panel*)). Interestingly, although the levels of LtgA or LtgA ^Δ30^ expressed from an ectopic locus in *N. meningitidis* were higher in comparison to the natively expressed protein, severe morphological defects were only observed in the Δ*ltgA^ltgA^*^Δ30^ strain.

![The LtgA helix 30 mutant shows morphological abnormalities.\
(**a**) Morphological differences between the wild type and strains expressing the mutant lytic transglycosylases were determined by fluorescence microscopy (*left panel*) and scanning electron microscopy (SEM) (right*panel*). White arrows in the images of *ΔltgA^ltgA^*^Δ30^ strain (*left panel*) point to cells defective in division and separation, as well as extracellular material. White arrows in the right panel points to, irregular cell surfaces, high-molecular-weight blebs (not observed in other strains), asymmetrical diplococci, and ghost cells (see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} for other images detailing additional morphological abnormalities). (**b**) Quantification of the confocal microscopy data. The different fields were manually counted to evaluate the number of cells per unit. Each unit is defined as an isolated cluster of cells that it is not in contact with other cells. Whenever in contact two cells were defined as apart of the same unit.](elife-51247-fig3){#fig3}

LtgA is involved in maintaining the structural composition of the peptidoglycan {#s2-3}
-------------------------------------------------------------------------------

We examined the PG profiles of wild-type *N. meningitidis*, Δ*ltgA*, Δ*ltgA^ltgA^* and Δ*ltgA^ltgA^*^Δ30^, to explore whether the integrity of the PG composition of Δ*ltgA^ltgA^*^Δ30^ strain was maintained. No notable differences were observed among the wild-type, Δ*ltgA* and Δ*ltgA^ltgA^* strains ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, Supplementary 1). However, the PG of the Δ*ltgA^ltgA^*^Δ30^ strain was found to be markedly hyperacetylated when compared to that of the other strains, with a 102% increase in the amount of acetylated GlcNAc-anhMurNAc-tetrapeptide (GM\*4), a 39% increase in acetylated GlcNAc-anhMurNAc-tetrapeptide crosslinked with GlcNAc-MurNAc-tetrapeptide (GM\*4-GM4), and a 46% increase in doubly acetylated di-GlcNAc-anhMurNAc-tetrapeptide (GM\*4 GM\*4) ([Figure 4](#fig4){ref-type="fig"}, [Figure 4b](#fig4){ref-type="fig"}). A 22% increase in the amount of GlcNAc-MurNAc tetrapeptide (GM4) was also observed, while the amounts of GlcNAc-MurNAc tripeptide (GM3) and GlcNAc-MurNAc pentapeptide (GM5) decreased by 33% ([Figure 4](#fig4){ref-type="fig"}, [Figure 4b](#fig4){ref-type="fig"}). Overall, there was a marked increase in the amounts of acetylated PG monomers and dimers.

![Muropeptide composition of PG isolated from wild-type and Δ*ltgA^ltgAΔ30^*.\
(**a**) The chromatogram represents purified PG digested by the muramidse, mutanolysin and the resulting muropeptides were reduced, and analyzed by LC/MS. The results were reproducible over four biological replicates. Peak identifications correspond to (**b**). Quantitation and analysis of muropeptides identified by mass spectrometry. \* indicates O-acetylated MurNAc. Acetylated GM\*4 is highlighted in bold. Multiple muropeptides coeluted as a single peak are shaded in pink. Red arrows indicate a decrease and blue arrows an increase in muropeptide abundance. The table displays the observed and theoretical masses and the proportion of total muropeptides.\
Figure 4---source data 1.Table associated with the muropeptide composition of PG isolated from wild-type, *ΔltgA, ΔltgAltgA.*\
Figure 4---source data 2.Raw data associated with themuropeptide composition of PG isolated from wild-type and Δ*ltgAltgAΔ30.*](elife-51247-fig4){#fig4}

The PG de-*O*-acetylase (Ape1) is the enzyme responsible for removing the *O*-acetyl group from the C6-hydroxyl position of the glycan strand of the *O*-acetylated PG and ensures the continued metabolism of the PG by LTs (LtgA, LtgD or LtgE and others) ([@bib58]; [@bib59]; [@bib32]; [@bib53]). Since the PG of the Δ*ltgA^ltgA^*^Δ30^ strain was hyperacetylated, the expression of Ape1 was assessed in all four strains (*N. meningitidis*, Δ*ltgA*, ΔltgA^ltgA^, Δ*ltgA^ltgA^*^Δ30^) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Ape1 was comparably expressed in all four strains ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

The impact of protein complexes on peptidoglycan O-acetylation {#s2-4}
--------------------------------------------------------------

Hyperacetylation of the PG was the most striking phenotype of the *ΔltgA^ltgA^*^Δ30^ strain. We therefore explored whether: 1) LtgA and Ape1 form a PG degrading complex, or 2) the normal function of Ape1 depends on LtgA, or 3) Ape1 and LtgA work in concert enzymatically to de-*O*-acetylate the PG. To accomplish this, we purified Ape1 and LtgA, following their heterologous expression in *E. coli* ([Figure 5a](#fig5){ref-type="fig"}). Each enzyme was purified individually and then combined prior to their application to size-exclusion columns ([Figure 5a](#fig5){ref-type="fig"}). LtgA formed an approximately 100 kDa complex with Ape1 ([Figure 5a](#fig5){ref-type="fig"}).

![LtgA stimulates and stabilizes the enzymatic activity of Ape1.\
(**a**) Chromatogram of the size exclusion analysis of purified (*panel 1*) LtgA, (*panel 2*)Ape1, (*panel 3*) Ape1-LtgA 105 kDa. Overlay of the chromatograms corresponding to purified LtgA, Ape1, and LtgA-Ape1 protein complex (*panel 4*). Each insert represents SDS-PAGE analysis of peak fractions containing proteins. Lanes are labeled with corresponding volumes. (**b**) Ape1 stimulates the activity of LtgA toward the acetylated PG of *N. meningitidis*. (**c**) LtgA stimulates and stabilizes Ape1 activity toward *p-*nitrophenol acetate. Ape1 utilizes *p-*nitrophenol acetate as a substratewhile LtgA does not. Error bars show the standard deviation of triplicate.\
Figure 5---source data 1.[Figure 5b](#fig5){ref-type="fig"} -- LtgA stimulation assay.\
Figure 5---source data 2.[Figure 5c](#fig5){ref-type="fig"} -- Ape1 stimulation assay.](elife-51247-fig5){#fig5}

We next examined the activity of LtgA and Ape1 against acetylated PG from *N. meningitidis,* or the activity of Ape1 alone, or Ape1 combined with LtgA toward 4-nitrophenyl acetate, a previously characterized substrate of Ape1 from *N. gonorrhoeae* that is not a substrate for LtgA ([@bib31]; [@bib60]). In the presence of equimolar (1.2 μM) amounts of Ape1, LtgA degrades the PG more efficiently ([Figure 5b](#fig5){ref-type="fig"}). This result is consistent with previous studies that suggest *O*-acetylation blocks the function of LTs and lysozyme ([@bib58]; [@bib59]; [@bib32]; [@bib53]). Surprisingly, in the absence of a common substrate and utilizing equimolar amounts (12 nM) of LtgA and Ape1, LtgA enhances the activity of Ape1 ([Figure 5c](#fig5){ref-type="fig"}). The reaction remained well within the linear range for 60 min when both enzymes were present, which was in stark contrast to Ape1, that showed less activity over the time course of 60 min. These data demonstrate that the enzymatic activities of LtgA and Ape1 are enhanced reciprocally when functioning together in a complex ([Figure 5c](#fig5){ref-type="fig"}). It also appears that LtgA stabilizes and enhance the activity of Ape1. Synergistic interaction between Ape1 and LtgA could reflect their coordinated function in PG structural regulation in vivo.

Interestingly, LtgA, along with other enzymes such as PBP1a, and LtgE are co-conserved in all the proteobacteria that were surveyed ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Meanwhile, Ape1 is exclusively co-conserved in *Neisseria, Kingella*, *Snodgrassell*a*, Morococcus*, *Azovibrio*, and one isolate of *Burkholderia ubortensis,* suggesting Ape1 in contrast to LtgA and others was potentially acquired later by lateral gene transfer ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

The source of helix 30 morphological defects {#s2-5}
--------------------------------------------

The activity of Ape one and LtgA appears to be synergistic. Since a Δ*ltgA* gave no noticeable phenotype, *Neisseria meningitidis* strains harboring a catalytically defective mutation of LtgA (E481A), or a Δ*ape1* strain of *N. meningitidis* were examined for morphological aberrations. The *ltgA* (E481A) strains showed no morphological abnormalities when compared to their parental strains ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). However, while the Δ*ape1* strain showed no significant defects in cell division or cell separation, cell shape abnormalities and lysed bacteria were clearly evident ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Additionally, in our previous study, we noted that diploid cells of the Δ*ape1* strain were larger compared to the wild-type strain ([@bib53]). Altogether these data suggest that Ape 1 is an important cell shape determinant.

Role of alpha helix 30 in the virulence of *N. meningitidis* {#s2-6}
------------------------------------------------------------

In *N. meningitidis* and *N. gonorrhoeae,* the activity of LtgA and other LTs leads to a release of cytotoxic PG fragments, which are detected by the host and induce a Nod1-dependent inflammatory response ([@bib11]; [@bib12]; [@bib19]; [@bib37]). Since the alpha helix 30-deleted strain of LtgA compromised the PG composition the functional role of the alpha helix 30 was explored in vivo in a mouse infection model. For this purpose, we used transgenic mice expressing human transferrin as an experimental model that allows meningococcal growth by providing a human iron source during infection. The four *N. meningitidis* strains (wild-type, Δ*ltgA^ltgA^*, Δ*ltgA^ltgA^*^Δ30^ and Δ*ltgA*) were used to infect the mice by intraperitoneal injection. Two hours after infection, the four strains induced similar levels of bacteremia ([Figure 6a](#fig6){ref-type="fig"}), suggesting that the strains were not defective in their ability to reach the bloodstream. The Δ*ltgA* strain appears to be cleared more slowly. However, the Δ*ltgA^ltgA^*^Δ30^ strain was cleared from the blood at a significantly faster rate than the other strains, exhibiting a 2-log difference in colony-forming units (CFUs) at the 6 hr time point compared to the wild-type strain ([Figure 6a](#fig6){ref-type="fig"}). These results were also consistent with those at the cytokine production level, as the Δ*ltgA^ltgA^*^Δ30^ strain exhibited significantly decreased levels of IL-6 and KC (the functional murine homolog of human IL-8) 6 hr after infection, while all the isolates exhibited similar levels 2 hr after infection ([Figure 6b](#fig6){ref-type="fig"}). Overall, the Δ*ltgA^ltgA^*^Δ30^ strain displays impaired fitness in the host, suggesting LtgA alpha helix 30 plays a key role in bacterial virulence.

![Helix 30 of LtgA plays a role in *N.meningitidis* host adaptation and virulence.\
*N.meningitidis* wild-type, *ΔltgA*, *ΔltgA^ltgA^* and *ΔltgA^ltgA^*^Δ30^ were administered to transgenic mice expressing human transferrin via an intraperitoneal route. (**a**) Bacterial burden was determined by enumeration of CFUs in blood 2, 6 and 24 hr pi. These data show that the strain complemented with a deletion in helix 30 is cleared faster than the other strains. (**b**) Pro-inflammatory cytokine (IL-6) and chemokine (KC) profile in blood of infected mice was evaluated 2, 6 and 24 hr post-infection by ELISA. The Δ*ltgA^ltgA^*^Δ30^ strain induced the production of lower levels of inflammatory mediators production upon infection compared to the other strains. Data represent three independent experiments with *n* = 5. Statistical analysis was done by Kruskal-Wallis non-parametric comparison against the complemented strain with a p-value\<0.01.\
Figure 6---source data 1.[Figure 6a](#fig6){ref-type="fig"} -- Quantification of bacterial burden.\
Figure 6---source data 2.[Figure 6b](#fig6){ref-type="fig"} -- Raw files associated with pro-inflammatory cytokines.](elife-51247-fig6){#fig6}

Discussion {#s3}
==========

Antibiotic resistance is recognized as an urgent global public health threat. One potential solution is to develop new treatment strategies that impact multiple cellular targets and consequently, circumvent the rise of antibiotic resistance. The bacterial cell wall is assembled by a number of enzymes, some of which are broadly categorized as PG polymerases, PG-modifying enzymes and PG hydrolases. The primary targets of β-lactams, clinically the most utilized antibiotics, are PBPs that are known to polymerize PG. The development of a combinatorial or single therapy that interferes with multiple cellular function of the PG machinery could define a new era in antibiotic development. This would be particularly relevant for *N. gonorrhoeae* infections, as no vaccines against this species are currently available, and highly resistant strains are on the rise. Indeed, a *N. gonorrhoeae* 'superbug' has already been identified that does not respond to the usual treatment with β-lactams such as ceftriaxone ([@bib42]).

In this study, we identified a variant of LtgA with a disordered active site alpha helix 30, which is important for PG binding and for the catalytic mechanism of LtgA ([Figure 1b](#fig1){ref-type="fig"}, [Video 1](#video1){ref-type="video"}). LTs are highly redundant enzymes, and when individual or multiple LTs are deleted, bacteria are known to proliferate normally because others LTs compensate for the loss of activity and/or function ([@bib11]; [@bib27]). Interestingly, when 6 LTs were deleted from *E. coli*, only a mild chaining phenotype was observed ([@bib22]); however, a mutant of *ltgC* with a 33 bp deletion at the 5′ end from *Neisseria* sp., showed defects in growth and daughter cell separation ([@bib12]). In our *ΔltgA^ltgA^*^Δ30^ strain, we observed significant defects in growth, cell division, cell separation, cell membrane irregularities, and fibrous and membranous extra cellular material, which were noticeably absent in the wild type, *ΔltgA,* and the Δ*ltgA^ltgA^* strains ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). LtgA has been shown to localize to the septum ([@bib37]), but no phenotype associated with cell division or cell separation was previously reported. However, the expression of an LT with impaired function (LtgA^Δ30^) results in the perturbation of various processes that are essential for bacterial proliferation.

Having observed that the *ΔltgA^ltgA^*^Δ30^ strain, but not the *ΔltgA* strain, was defective in growth, cell separation, and cell division, we then analyzed the PG profiles of wild-type *N. meningitidis*, Δ*ltgA*, Δ*ltgA^ltgA^* and Δ*ltgA^ltgA^*^Δ30^, and observed that Δ*ltgA^ltgA^*^Δ30^ strain was hyperacetylated and there was an increase in PG monomers ([Figure 4](#fig4){ref-type="fig"}, [Figure 4b](#fig4){ref-type="fig"}). Since the hyperacetylation of the PG was the most striking phenotype, we analyzed the functional relationship between LtgA and Ape1. The interaction between LtgA and Ape1 was not unexpected because Ape1, a PG-de-*O*-acetylase, removes the *O*-acetyl group from the C6-hydroxyl position of the glycan strand of *O*-acetylated PG and ensures the continued metabolism of the PG by LTs (LtgA, LtgD or LtgE and others) ([@bib58]; [@bib59]; [@bib32]; [@bib53]). Based on the hyperacetylation of the PG, we hypothesized that a functional LtgA is needed to stablize the activity of Ape1 and together they work in concert to ensure the proper metabolism of the PG ([Figure 5b--c](#fig5){ref-type="fig"}). To test this, we used 4-nitrophenyl acetate, a known substrate of Ape1 but not LtgA. Surprisingly, LtgA enhances the activity and function of Ape1 well past the normal range (1 hr) of most in vitro enzymatic reactions, giving clear evidence that LtgA could orchestrate the activity, and function of Ape1 ([Figure 5b--c](#fig5){ref-type="fig"}). Since Ape1 and LtgA activity appears to be synergistic, we examined whether the abberant phenotype of the *ΔltgA^ltgA^*^Δ30^ strain could be related to the malfunction of Ape1. Similar to the *ΔltgA^ltgA^*^Δ30^ strain, the *Δape1 strain* showed clear cell membrane irregularities; however, there were no significant defects in cell division or separation ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). The observed cell membrane irregularities of the *ΔltgA^ltgA^*^Δ30^ strain ([Figure 3](#fig3){ref-type="fig"}) could be due to the malfunction of Ape1, and defects in cell division or separation could be linked to a dysfunctional LtgA. A recent study showed that in *Vibrio cholerae*, LTs RlpA and MltC similar to LtgA both localize to the septum and contribute to daughter cell separation suggesting that during septal PG synthesis glycan strands are formed between daughter cells ([@bib61]).

Our study revealed an intimate relationship between LtgA and Ape1, ie. LtgA enhances the activity of Ape1 and an impaired LtgA results in a dysfunctional Ape1, and appears to poison the cell wall machinery with devastating effects toward the survival of *Neisseria in the host*.

Finally, to understand what role a defective LtgA that interferes with the normal function of the PG machinery plays in the pathogenesis of *N. meningitidis*, we used a mouse infection model and showed Δ*ltgA^ltgA^*^Δ30^ strain of *N. meningitidis* was cleared from the blood at a significantly faster rate than the wild-type, Δ*ltgA^ltgA^* or Δ*ltgA* strains. Consistent with the virulence phenotype, and in comparison to the other three strains, the Δ*ltgA^ltgA^*^Δ30^ strain in mice resulted in significantly decreased levels of IL-6 and KC, and decreased bacterial load in the blood at 6 hr post-infection ([Figure 6a--b](#fig6){ref-type="fig"}), indicating a loss of fitness of the helix-30 deleted mutant strain in the host.

One possible explanation for the differences in bacterial load after 6 hr in the helix-30 deleted strain is bacterial clearance mediated by the complement system. It is well accepted that *Neisseria meningitidis* is eliminated from the blood through complement lysis ([@bib40]). Generally, individuals with complement lysis difficiencies are at a higher risk for invasive meningococcal disease. Additionally, the helix deleted strain is hyperacetyaled and it is known that modification of the PG makes the cell wall more susceptible to complement-mediated lysis ([@bib65]; [@bib35]), and PG modification is also associated with a decreased inflammatory response ([@bib44]).

In summary, Ape1's activity is enhanced by LtgA. An impaired LtgA disrupts the function of Ape1, the normal course of bacterial cell division or cell separation ([Figure 7a-c](#fig7){ref-type="fig"}), paving the way for the design of inhibitors or antibiotics that target LTs.

![Peptidoglycan degrading complexes can modulate enzymatic function.\
(**a**) The removal of the *O*-acetyl group by Ape1 allows LtgA to efficiently metabolize the PG. There was normal cell growth, division and separation (yellow triangle represent acetyl groups, glycan strand are colored in green and orange, and stem peptides are represented in blue and yellow circles). (**b**) Removal of LtgA does not affect the function of Ape1. Normal cell growth, division and or separation was observed. (**c**) Deletion of alpha helix 30 of LtgA affects the function of Ape1, disrupts, growth, cell division and cell separation and bacterial survival in the host.](elife-51247-fig7){#fig7}

Conclusion {#s3-1}
----------

We devised a multidisciplinary approach using structural biology to show that it is possible to target a 'hot spot' on an LT in order to affect bacterial growth, cell division, and cell membrane integrity ([Figure 7a-c](#fig7){ref-type="fig"}), which resulted in lethal consequences for the bacteria during host infection. Additionally, as we discovered with Ape1, LTs can regulate the function and activity of their protein binding partners, revealing an additional role for LTs in the bacterium . This study shows the ripple effects of disrupting LtgA PG binding capabilities and sets the stage for future development of a class of antibiotics that may act by a dual action in vivo. A small molecule binding to alpha helix 30 could interfere with growth and simultaneously promote bacterial clearance, mimicking the enhanced clearance of the *ltgA^ltgA^*^Δ30^ mutant in a murine infection model.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                              Designation                                        Source or reference                                                             Identifiers                                                    Additional\
  (species) or resource                                                                                                                                                                                                                                        information
  ---------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------
  Gene (include species here)                                ltgA (*Neiserria*\                                 This paper                                                                                                                                     
                                                             *meningitidis MC58/*8013)                                                                                                                                                                         

  Strain, strain background (include species and sex here)   *ltgA^ltgA^*^Δ30^\                                 This paper                                                                                                                                     
                                                             *Neiserria meningitidis MC58/*8013)                                                                                                                                                               

  Strain, strain background (include species and sex here)   *ltgA^ltgA^* (*Neiserria meningitidis MC5/*8013)   This paper                                                                                                                                     

  Strain, strain background (include species and sex here)   *^ΔltgA^* (*Neiserria meningitidis MC58/*8013      This paper                                                                                                                                     

  Strain, strain background (include species and sex here)   ^*Δape1*^*Neiserria meningitidis MC58*             doi:[10.1111/mmi.12153](https://doi.org/10.1111/mmi.12153)                                                                                     

  Strain, strain background (include species and sex here)   ^*ltgA(E481A)*^*Neiserria meningitidis* 8013       This paper                                                                                                                                     

  Antibody                                                   LtgA Guinea pig polyclonal Antibody                This paper                                                                                                                                     1:250

  Antibody                                                   Ape1 mouse polyclonal Antibody                     This paper                                                                                                                                     1:250

  Recombinant DNA reagent                                    pGEX-4T1-LtgA                                      doi: [10.3390/antibiotics6010008](https://doi.org/10.3390/antibiotics6010008)                                                                  

  RecombinantDNA reagent                                     pGEX-4T1-Ape1                                      doi:[10.1111/mmi.12153](https://doi.org/10.1111/mmi.12153)                                                                                     

  Software, algorithm                                        GraphPad\                                                                                                                          RRID:[SCR 002798](https://scicrunch.org/resolver/SCR_002798)   <https://www.graphpad.com/scientific-software/prism/>
                                                             Prism                                                                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein expression and purification {#s4-1}
-----------------------------------

All constructs were created using standard molecular biological techniques. All constructs used for protein expression and purification in this study were GST fusions expressed from pGEX-4T1 (GE Life Sciences). The native proteins without signal peptides were expressed in BL21(DE3) Gold competent cells (Novagen). The gene encoding the LtgA deletion mutant lacking the alpha helix ^503^(ATAREIAGKIGMD)^513^ was chemically synthesized by ProteoGenix. The synthesized *ltgA* alpha helix deletion gene was cloned into a GST-fusion pGEX-4T1 (GE Life Sciences) plasmid as described above. The expression of all constructs was induced with 0.6 mM IPTG at an optical density at 600 nm (OD600) of 0.7--0.8 and harvested after 4 hr of induction at 18°C. After glutathione-affinity chromatography and thrombin cleavage, proteins were purified to homogeneity by size-exclusion chromatography (Superdex-200, GE) in 50 mM HEPES (pH 7.4), 150 mM NaCl, and 1 mM BME. After gel filtration, the proteins were immediately used for crystallization or flash frozen in liquid nitrogen and stored at −80°C.

X-ray crystallography {#s4-2}
---------------------

Crystallization screening was carried out by the sitting-drop vapor-diffusion method with a Mosquito (TTP Labtech) automated crystallization system. All crystals were grown at 18°C using the hanging-drop vapor-diffusion method. Crystals of 15--20 mg/ml LtgA were grown at 18°C and appeared within 2--3 days. LtgA was crystallized in a 1:1 (v/v) ratio against a well solution of 33% (w/v) PEG 6000 and 100 mM HEPES, pH 7.5. Crystals were rectangular in shape and grew to approximately 200--300 μm in length.

The data set was collected at the Soleil Synchrotron (Beamline Proxima-1) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Phasing by molecular replacement was performed using Phenix ([@bib1]). Building was performed using Coot ([@bib17]), and restrained refinement was carried out using a combination of Phenix and the ccp4 software suite ([@bib1]; [@bib13]). MolProbity was used during building and refinement for iterative structure improvements ([@bib14]).

All structural figures were generated with PyMOL (PyMOL Molecular Graphics System, version 1.5, Schrödinger, LLC). The crystallographic parameters, data statistics, and refinement statistics are shown in [Supplementary file 2](#supp2){ref-type="supplementary-material"}. Modeling of unknown LTs were accomplished using Phyre 2 ([@bib24]). Videos of the LtgA enzymatic steps were generated in PyMOL and then assembled in photoshop and edited in iMovie.

Protein-protein interaction studies by gel filtration {#s4-3}
-----------------------------------------------------

To explore the interactions of LtgA and its PG binding partners, proteins were mixed at equimolar concentrations of 10 µM, incubated on ice for 1 hr, and subjected to gel filtration chromatography on an SD200 10/300 column. Approximately 150--300 µl of each sample was applied to the column in 50 mM HEPES (pH 7.5) and 150 mM salt. Peak fractions were then subjected to SDS-PAGE (5--15%) analysis.

Analysis of *Neisseria* sp. peptidoglycan by reversed-phase HPLC and mass spectrometry {#s4-4}
--------------------------------------------------------------------------------------

The peptidoglycan isolated from all four strains (wild-type, *ΔltgA*, Δ*ltgA^ltgA^* and Δ*ltgA^ltgA^*^Δ30^) was incubated for 16 hr in the presence of 10 µg of mutanolysin in 12.5 mM sodium phosphate buffer (pH 5.6) at 37°C (total reaction volume 150 µl). The reaction was stopped by boiling the samples for 3 min, and the supernatant containing the soluble muropeptides was collected after centrifugation at 16,000 ×*g* for 10 min. The supernatant was analyzed by reversed-phase HPLC using a Hypersil GOLD aQ column (5 μm particle size, 150 × 4.6 mm, flow rate 0.5 ml at 52°C, Thermo Fisher Scientific) with a mobile phase of H~2~O-0.05% trifluoroacetic acid and a 25% acetonitrile gradient over 130 min. Muropeptides of interest were collected and identified by mass spectrometry as previously described ([@bib63]; [@bib64]).

Bacterial strains {#s4-5}
-----------------

Clone 12 is a derivative of strain 8013, a serogroup C *N. meningitidis* strain ([@bib30]), and MC58 is a serogroup B strain ([@bib47]). Bacteria were grown on GCB medium (Difco) containing Kellogg\'s supplements ([@bib25]). The *E. coli* strain DH5 ([@bib21]) was used for plasmid preparation and subcloning. Kanamycin, ampicillin and erythromycin were used in *E. coli* at final concentrations of 50, 100 and 300 µg/ml, respectively. In *N. meningitidis*, kanamycin, ampicillin and erythromycin were used at final concentrations of 2, 20 and 100µg/ml, respectively.

Plasmid construction {#s4-6}
--------------------

The *ltgA* gene (1851 nucleotides according to the genome sequence of the meningococcal strain MC58) was chemically synthesized with a deletion of 42 bp (14 codons) between positions 1506 (codon 502) and 1548 (codon 516) (starting at ATG) and was cloned into the vector pUC57 to generate the recombinant plasmid pUC57ltgA (ProteoGenix, Schiltigheim, France). The *ltgA* fragment was amplified using the primer pair NMF1/NMR1 from the plasmid pUC57ltgA and from the strain MC58. The two fragments were blunt-ended using the Klenow DNA polymerase fragment (BioLabs) and subcloned into the *BamH*I site of the recombinant plasmid pTE-KM ([@bib45]). This plasmid contains the *pilE* gene of clone 12 with the Km cassette, encoding resistance to kanamycin, located immediately downstream of the *pilE* without modification of *pilE* expression. Moreover, a unique BamHI site located between the Km cassette and the downstream region at the 3' end of the *pilE* gene ([@bib30]; [@bib45]) was used to subclone the two blunt-ended fragments from the plasmid pUC57ltgA and from the strain MC58 to yield the recombinant plasmids pD-Δ*ltgA^ltgA^* and pD-Δ*ltgA^ltgA^*^Δ30^, respectively.

An internal deletion in the *ltgA* gene was also constructed by removing the segment between the restriction sites BsmI (position 21) and BalI (position 1724) on pUC57ltgA, and this region was replaced with the *ermAM* cassette, encoding erythromycin resistance; the construct was checked using the primer pair ERAM1/ERAM3 (5'-gcaaacttaagagtgtgttgatag-3' and 5'-aagcttgccgtctgaatgggacctctttagcttcttgg-3', respectively) ([@bib45]). The corresponding recombinant plasmid pDG15-09 was linearized at the *EcoR*I site of the pUC57 vector and used to transform the clone 12 strain of *N. meningitidis*. Transformants were selected on standard GCB medium in the presence of 2 µg/ml erythromycin. Integration by homologous recombination into the *ltgA* gene on the meningococcal chromosome was further confirmed by PCR analysis using the oligonucleotides ERAM1/ERMA3 and NMF1/NMR1. One transformant was selected for further analysis and named pD-ΔltgA.

The two recombinant plasmids pD-Δ*ltgA^ltgA^* and Δ*ltgA^ltgA^*^Δ30^ were linearized using the ScaI restriction enzyme and used to transform the strain pD-*ΔltgA*. Transformants were selected on standard GCB medium in the presence of 2 µg/ml erythromycin and 100 µg/ml kanamycin. Integration by homologous recombination into the *ltgA* gene on the meningococcal chromosome was further monitored by PCR analysis using the oligonucleotides pilE1, NMF1, NMR1 and NMF1/NMR1. One transformant from each transformation was selected for further analysis and named Δ*ltgA^ltgA^* or Δ*ltgA^ltgA^*^Δ30^. The strain Δ*ltgA^ltgA^* has the *ltgA* gene deleted from its locus but harbors the *ltgA* gene downstream of the *pilE* site. The Δ*ltgA^ltgA^*^Δ30^ strain also has the *ltgA* gene deleted from its locus and contains a downstream *pilE* gene but harbors the *ltgA* gene with the region encoding the amino acid residues 501--516 deleted.

Strains 8013 expressing mutant lytic transglycosylases (E481A) were constructed by transformation with plasmid pRS91 ([@bib37]) containing the E481 mutation. Potential transformants were screened by PCR amplification of active site region followed by digestion with Hyp188III. Positive transformants that lacked a Hyp188III site at the active site were confirmed by sequencing.

The MC58 *Δape1 strain* was described in our previous study ([@bib53]). Briefly, the entire *pat* operon which consists of *patA*, *patB* and *ape1* was deleted in MC58 and then this knockout mutant was complemented by the introduction of *patA* and *patB genes.*

Fluorescent labeling and fluorescent microscopy {#s4-7}
-----------------------------------------------

Bacterial cultures were centrifuged 5 min at 5000 rpm and re-suspended in PBS containing 1 µg/mL DAPI and 5 µg/ml FM4-64 FX (*N*-(3-Triethylammoniumpropyl)−4-(6-(4 (Diethylamino) Phenyl) Hexatrienyl) Pyridinium Dibromide) probe. The cells were incubated for 10 min at room temperature protected from light, centrifuged and the pellets resuspended in 4% PFA for fixation during 5 min. After fixation, the cells were washed with PBS, and a 10 µL drop of the bacterial suspension was applied onto poly-L-Lysine pre-coated cover glasses (\# 1.5). Next, samples were mounted using Prolong Diamond and imaged using Leica SP5 confocal microscope, with a 63X (1.4 NA) oil-immersion objective using 405 nm and 514 nm laser lines. Fluorescence was recorded sequentially using hybrid (HyD) detectors and images processed using Fiji ([@bib39]).

Scanning electron microscopy {#s4-8}
----------------------------

*Neisseria meningitidis* was prefixed in 2.5% Glutaraldehyde diluted in PHEM (Pipes, Hepes, EGTA and MgSO~4~) buffer at pH 7. The cells were prefixed for 1 hr at room temperature, followed by two washes in PHEM buffer. The samples were applied onto the cover glass (1.5 mm) pre-coated with poly-L-Lysine. This was followed by a low speed centrifugation to ensure that the cells adhere correctly to the cover slip.

The bacteria were post-fixed using 2% osmium tetroxide in PHEM buffer for 30 to 60 min followed by washing with water three times. The specimen was dehydrated using increasing ethanol concentrations of 25% to 100% in increments of 25%. The bacteria were critically point dried using carbon dioxide, coated with gold and examined with the JEOL JSM‐6700F scanning electron microscope.

*O*-acetyl peptidoglycan esterase assay {#s4-9}
---------------------------------------

The acetyl esterase activity assays were executed as previously described with minor modifications ([@bib31]; [@bib20]). Briefly, the reaction utilized 2 mM 4-nitrophenyl acetate as the substrate. The reaction was carried out at 37°C in 50 mM sodium phosphate buffer, pH 6.5 in the presence of LtgA, using equimolar amounts of LtgA and Ape1 or Ape1. The final volume of the reaction was 300 μl. The reaction was initiated with the addition of the substrate 4-nitrophenyl acetate dissolved in 5% v/v ethanol. The release of 4-nitrophenyl was monitored over the time course of an hour in 96 well microtiter plate at an absorbance of 405 nm.

Analysis of LtgA activity {#s4-10}
-------------------------

To assess the activity of LtgA, PG (200 µg) was incubated in the presence of LtgA, or equimolar amounts of LtgA and Ape1, in 12.5 mM sodium phosphate buffer pH 5.6. *Neisseria* PG was purified as previously described ([@bib62]). The reaction mix was initiated by the addition of enzymes and incubated at 37°C for 5 min. Control reactions lacking PG or enzyme/inhibitor were also included. The final reaction volume was 200 µL. Reactions were performed in triplicates. The reaction was stopped by incubating the samples in a heat block at 100°C for 5 min. The soluble 1,6-anhydro-muropeptides was collected using centrifugation at 16,000 *g* for 10 min at room temperature. The supernatant was collected and analyzed by reversed-phase HPLC using a Shimadzu LC-20 system with a Hypersil GOLD aQ column (5 μm particle size, 250 × 4.6 mm, flow rate 0.5 mL/mL at 52°C; Thermo Fisher Scientific (Waltham, MA, USA). The mobile phase gradient was 50 mM sodium phosphate pH 4.3 to 75 mM sodium phosphate pH 4.9 with 15% Methanol over 135 min.

Infection model {#s4-11}
---------------

A previously published model for meningococcal infection in transgenic mice expressing human transferrin was used ([@bib43]). Four strains were tested: clone 12 (wild-type), Δ*ltgA^ltgA^*, Δ*ltgA^ltgA^*^Δ30^ and *ΔltgA*. Five mice per group were infected by intraperitoneal injection with 500 µl of bacterial suspension of each strain at 1 × 10^7^ CFU/ml. Blood samples were obtained by retro-orbital bleeding after 2, 6 and 24 hr, and bacterial counts were determined by plating serial dilutions on GCB medium.

Phylogenetic tree construction {#s4-12}
------------------------------

Protein sequences were aligned using MUSCLE alignment algorithm using UPGMA clustering method in MEGAX ([@bib26]). Using aligned sequences, a maximum likelihood tree was constructed using a Neighbor joining construction method and a JTT protein substitution model in CLC Genomics Workbench 8.01. Robustness was estimated using 500 bootstrap replicates (values not shown in figures).

Ethics statement {#s4-13}
----------------

Animal work in this study was carried out at the Institut Pasteur in strict accordance with the European Union Directive 2010/63/EU (and its revision 86/609/EEC) on the protection of animals used for scientific purposes. The laboratory at the Institut Pasteur has the administrative authorization for animal experimentation (Permit Number 75--1554) and the protocol was approved by the Institut Pasteur Review Board that is part of the Regional Committee of Ethics of Animal Experiments of Paris Region (Permit Number: 99--174). All the invasive procedures were performed under anesthesia and all possible efforts were made to minimize animal suffering.

Cytokine assay {#s4-14}
--------------

Blood samples from infected mice were collected and stored at −80°C. Cytokines (IL-6 and KC) were quantified by an enzyme-linked immunosorbent assay (Quantikine; R and D Systems Europe, Abingdon, Oxon, United Kingdom).

Growth curves and LtgA stability assay {#s4-15}
--------------------------------------

Bacteria were grown overnight in GC broth with Kellogg\'s supplements at 37°C and 5% CO~2~. Fresh medium was inoculated at an OD600 of 0.05, and growth was measured spectrophotometrically at 1 hr intervals over a period of 24 hr at 37°C and 5% CO~2~. When indicated, 2 µg/ml chloramphenicol was added when the OD~600~ reached 0.6, and incubation was continued at 37°C and 5% CO~2~. At different incubation time points, aliquots (3 ml) from each culture were sampled, and the bacteria were collected by centrifugation, lysed by boiling in SDS-containing sample buffer, and analyzed for the presence of LtgA by western blotting using anti-LtgA antibodies. The expression of the outer membrane factor H binding protein (Fhbp) was used as an internal control.

PG binding assay {#s4-16}
----------------

The binding of the different LtgA proteins to PG was carried out by incubating 100 µg of PG and 10 µg of enzymes suspended in 150 µl of Tris buffer pH 7.5 (10 mM Tris, 10 mM MgCl~2~ and 50 mM NaCl). After 30 min of rocking at room temperature, 50 µl of the sample was set aside for analysis before centrifugation for 10 min at 20,000 x*g*. The supernatant was discarded, and the insoluble fraction was washed three times. The remaining pellet was boiled for 10 min. Five microliters of the input or unbound and bound fractions was loaded on an SDS-PAGE gel and analyzed by western blotting.

Accession numbers {#s4-17}
-----------------

Coordinates and structural data have been submitted to the Protein Data Bank under the accession code 6H5F.
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###### Crystallography data collection and refinement statistics of LtgA.
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Coordinates and structural data have been submitted to the Protein Data Bank under the accession code 6H5F.
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**Acceptance summary:**

The surge in antimicrobial resistance, together with the emergence of new pathogenic species continues to occupy global public health authorities, all of whom have issued an urgent call for new antimicrobials with novel modes of action. In this backdrop, bacterial peptidoglycan remains a tractable area for new drug development given the proven clinical benefit of drugs that target this macromolecule. This study, which describes how an alpha helix from the peptidoglycan remodelling enzyme, LtgA, can modulate cell wall stability highlights how the careful coordination of cell wall assembly and hydrolysis can be targeted by modulating the activity of hydrolases that remodel the cell surface. The conservation of similar motifs or regulatory patterns across different species suggests that this approach can be used to identify new drug targets in several bacterial pathogens.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for submitting your work entitled \"Crippling the bacterial cell wall molecular machinery\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

The reviewers highlighted some interesting aspects of your work, chief among which included some novel insight on the function of LtgA, based on structure-function associations. However, there were notable concerns regards the lack of sufficient data to support the conclusions regarding the role of LtgA in coordinating peptidoglycan hydrolysis. Further, the focus of the paper did not seem to fit with the data presented.

Reviewer \#1:

Summary:

Peptidoglycan (PG), a biopolymer made up of cross-linked sugars and stem peptides, is a widely distributed component of bacterial cell walls. Remodelling of this polymer requires the concerted action of a variety of PG synthesising and hydrolysing enzymes. Lytic transglycosylases are a family of PG hydrolases that break down the glycan component. These enzymes usually occur in bacteria in genetic redundancy. In their submission, Williams and colleagues describe the function of LtgA, a lytic transglycosylase, in *Neisseria meningitidis*. They build on previous findings that describe the crystal structure of this protein and describe a role for LtgA in regulating divisome function and virulence.

Key findings:

1\) The description of an atomic structure of LtgA with a disordered alpha helix 30, which is involved in clamping the glycan strand during catalysis. Mutation of this helix decreases the affinity of the protein for PG.

2\) Deletion of helix 30 affected growth of *N. meningitidis*, this was associated with cell division and morphological defects?

3\) Removal of this helix also results in hyperacetylation of the peptidoglycan.

4\) LtgA interacts with ApeI (a peptidoglycan-de-*O*-acetylase) and PBP1a (a high molecular weight penicillin binding protein).

5\) LtgA and ApeI appear to enhance each other\'s function in a reciprocal manner.

6\) Removal of helix 30 attenuated *N. meningitidis* for colonization of mice -- as measured by bacteraemia in the blood -- and altered induction of IL-16 and KC.

Conclusion: LtgA forms an important component of the divisome and regulates the function of other PG modifying enzymes.

Major concerns:

1\) The morphological defects in Figure 1 need to be quantified, followed by a statistical comparison to wild type and the *ltgA* complement derivatives. How many cells had these observations? How many ghost cells were observed?

2\) Figure 7 needs statistics for the cytokines.

3\) IL-6 is proinflammatory cytokine, in most cases. The LtgA helix 30 mutant has reduced production of IL-6 (Figure 7). In this context, the statement in the Discussion (paragraph seven) that this mutant version of LtgA has pro-inflammatory potential does not make sense. The mouse phenotypes are somewhat unclear -- reduced inflammation but longer persistence of the helix 30 mutant. There is a lot of conjecture in the discussion -- but little evidence to substantiate the claims made.

Reviewer \#2:

The manuscript entitled, \"Crippling the bacterial cell wall molecular machinery\". by Williams et al. describes the function of a truncation mutant in LtgA that removes alpha helix 30. While the finding may eventually turn out interesting, but at this point the inconsistencies and poor quality of the writing makes it impossible to fully understand the work. For example, the authors describe a number of proteins that bind the Δ30 protein, but not the wildtype protein, based on Figure 5. However, they go on to validate the binding of these proteins to the wildtype LtgA in Figure 6 not the mutant. They also claim that the Δ30 strain was cleared faster in mice, but they don\'t account for the slower growth rate of this crippled strain. There are many other problems with the work that needs to be ironed out before this could be considered for publication.

Reviewer \#3:

The paper by Williams and colleagues follows up on a previous study that reported the structure of the lytic transglycosylase (LT) LtgA from *Neisseria* species. LT enzymes cut bonds in the peptidoglycan (PG) cell wall layer, but their precise role(s) in the overall process of PG biogenesis have remained elusive. Here, the authors report a variant of the LtgA structure in which an alpha-helix in the active site (H30) is disordered. It is thought that this structure may represent an intermediate in the catalytic mechanism of the enzyme. To further investigate the importance of H30 for LtgA function, a variant of the enzyme with H30 deleted (LtgA^Δ30^) is constructed and expressed in a *Neisseria* strain deleted for the native *ltgA* gene. Surprisingly, while the loss of LtgA function causes little to no phenotype, expression of LtgA^Δ30^ causes a severe growth defect and major problems with cell division/separation. Cells producing LtgA^Δ30^ are found to contain elevated levels of acetylation in the PG sugars. They are also defective in pathogenesis. Co-immunoprecipitation followed by proteomics was performed to identify interaction partners of LtgA^Δ30^ and LtgA (wild type). Although there were no significant hits for LtgA (wild type), LtgA^Δ30^ associated with other factors involved in PG biogenesis. in vitro studies were performed to show that LtgA (wild type) can interact with some of the factors identified in the proteomic study. Another factor Ape1, a PG deacetylase, was also shown to interact with LtgA (wild type) in vitro, but the interaction was not observed in the proteomic analysis. Finally, LtgA (wild type) was shown to enhance the deacetylase activity of Ape1.

From the results of these experiments the authors conclude that LtgA mediates the function of a hub of PG glycan strand modifying enzymes, orchestrates cell division, cell wall integrity, and contributes to pathogenicity. Although there are several interesting aspects to this study, most of these stated conclusions are not justified by the data. I believe the authors should carefully reconsider their interpretation of the results and consider changing the focus of the manuscript to the Ape1-LtgA connection.

My major concerns are as follows:

1\) The observation that deletion of *ltgA* has no phenotype but that LtgA^Δ30^expression is detrimental to growth indicates that a defective LtgA is worse than not having it at all. One cannot conclude from this observation that LtgA orchestrates cell division, cell wall integrity, or the function of an important enzymatic complex. If this were true, then the loss of *ltgA* function would result in division and cell wall defects. The more likely explanation of the results is that the catalytically defective LtgA^Δ30^ binds glycans and/or components of the PG biogenesis machinery and somehow impairs their function. Thus, the finding that LtgA^Δ30^ expression is detrimental provides a clue to LtgA function, but more information about the mechanism behind the dominant-negative phenotype is needed to make strong statements/conclusions about LtgA\'s role in the cell. At present, it is hard to tell whether or not the detrimental effects of LtgA^Δ30^ production has anything to do with its normal function, especially since it is expressed at about 3-5x greater concentration than the native enzyme in the reported experiments.

2\) I think it is important to know whether an active site point mutant of LtgA has a similar phenotype to LtgA^Δ30^. This will help determine whether LtgA^Δ30^ is special in some way, or if any catalytically defective enzyme will cause similar effects on cell division etc.

3\) The observation that LtgA interacts with PBP1a and LtgE in vitro is interesting. However, none of the results indicate that these interactions have a functional consequence in cells or on the enzymes in vitro. Thus, the conclusion that LtgA mediates the function of a hub of PG glycan strand modifying enzymes is not an appropriate one to make without further studies.

Given that LtgA^Δ30^ expression affects PG acetylation in cells and LtgA promotes the activity of the deacetylase Ape1 in vitro, there is a much more convincing functional connection between these enzymes. I would therefore recommend rewriting the paper to focus on the dominant negative phenotype of LtgA^Δ30^ and potentially other catalytically defective LtgA variants and how this uncovered a connection with Ape1 function.

4\) There is a disconnect between the co-immunoprecipitation/proteomic results and the in vitro SEC experiments. The co-IP data indicate that only LtgA^Δ30^ associates with PBP1a and other proteins, yet the SEC experiments are performed with LtgA (wild type). If the LtgA (wild type) is capable of interacting with these proteins, why did they not show up as hits in the proteomic analysis? Does LtgA^Δ30^ have a greater affinity for the interaction partners identified? This discrepancy raises concerns about the validity and reproducibility of the proteomic experiments.

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Crippling the bacterial cell wall molecular machinery\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Gisela Storz (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

Please note that while we are asking for a substantial number of items to be addressed, we remain overall positive about the work, and are of the opinion that this all very doable within a reasonable time frame.

Summary:

The revised manuscript from Williams and colleague describes the role of the helix 30 structural motif in LtgA, a lytic transglycosylase from *Neisseria meningitidis*. Expression of a variant from of LtgA, with the helix 30 deleted, resulted in altered cell wall stability, defective cell separation, reduced virulence and hyperacetylated peptidoglycan. The authors conclude that expression of this defective version of LtgA modulates the function of the peptidoglycan de-*O*-acetylase, Ape1. Whilst some of the issue raised during the first round of review have been addressed, the following issues need attention for the manuscript to be considered further at *eLife*:

Major issues requiring new experimentation:

1). The focus on the LtgA-Ape1 connection in the revised manuscript represents a major step in the right direction. However, with this renewed focus, it becomes important to provide some data that helps explain why Ape1 activity appears to be negatively impacted by expression of the LtgA^Δ30^ mutant. At a minimum, Ape1 levels should be assessed by western blot to determine whether or not it is stably expressed in these cells.

2\) Additional support for the model that Ape1 is activated by LtgA in vivo should also be provided by examining whether or not Ape1 depletion results in a morphological defect that resembles that induced by the LtgA^Δ30^ mutant.

3\) Testing whether or not expression of a catalytically defective LtgA mutant induces the same phenotype as the LtgA^Δ30^ mutant is an important experiment. It will indicate whether or not there is something special about the LtgA^Δ30^ mutant or if any catalytic defect will cause the observed effects. This experiment is not a difficult one, and given its importance, is not beyond the scope of the current manuscript or a subject for further study.

4\) The title of the manuscript is too vague and does not convey any useful information to a potential reader. Consider something sharper and more on-point such as, \"A catalytically defective variant of a lytic transglycosylase disrupts cell morphogenesis by interfering with peptidoglycan deacetylation in Neisseria meningitidis\". Or something similar to this effect.

10.7554/eLife.51247.sa2

Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> Reviewer \#1:
>
> \[...\]
>
> Major concerns:
>
> 1\) The morphological defects in Figure 1 need to be quantified, followed by a statistical comparison to wild type and the ltgA complement derivatives. How many cells had these observations? How many ghost cells were observed?

We thank the reviewer for this keen observation. We made the quantification of the morphological abnormalities observed by confocal microscopy. Please see Figure 3. We were unable to do the same for the scanning electron microscopy because in this panel we took high-resolution images of the individual cells or cell clusters to get a closer look at the morphological defects. The ghost cells could be observed in all the clusters we scanned. An approximation of the ratio of ghost to intact cells is 1:10.

> 2\) Figure 7 needs statistics for the cytokines.

This has been updated. The statistical analysis was done by Kruskal-Wallis non-parametric comparison against the complemented strain with a *p*-value \< 0.01. Figure 7 is now the new Figure 6 in the revised manuscript.

> 3\) IL-6 is proinflammatory cytokine, in most cases. The LtgA helix 30 mutant has reduced production of IL-6 (Figure 7). In this context, the statement in the Discussion (paragraph seven) that this mutant version of LtgA has pro-inflammatory potential does not make sense.

We thank the reviewer for this astute observation. This sentence has been deleted in the Discussion. The paper has been refocused and the discussion has been revised.

> The mouse phenotypes are somewhat unclear -- reduced inflammation but longer persistence of the helix 30 mutant. There is a lot of conjecture in the discussion -- but little evidence to substantiate the claims made.

We apologize if this was unclear, however, infection with the helix-30 mutant did not result in longer persistence in the blood stream but it was cleared at a faster rate. See Figure 6. We have refocused the paper and modified the Discussion.

> Reviewer \#2:
>
> The manuscript entitled, \"Crippling the bacterial cell wall molecular machinery\". by Williams et al. describes the function of a truncation mutant in LtgA that removes alpha helix 30. While the finding may eventually turn out interesting, but at this point the inconsistencies and poor quality of the writing makes it impossible to fully understand the work.

1)We thank the reviewer for the comments, but we disagree with this assessment. Based on structural knowledge we demonstrate how an LT (LtgA) can be manipulated to affect the integrity of the cell wall composition, create a defect in cell division and separation, and can be manipulated to impair the fitness of the human pathogen *Neisseria meningitidis* during infection. Our study shows that targeting LTs disrupts the function of its binding partner Ape1 whose stability and activity depends on LtgA. We demonstrate in this verified case, that besides degrading the PG, peptidoglycan degrading enzyme complexes can modulate their enzyme function and stability. These findings highlight the importance of these PG complexes in *Neisseria* biology and virulence, demonstrating their potential as future targets for drug development.

2\) We are sorry that it was unclear, and we have taken significant steps to revise the manuscript both in focus and discussion. The revised paper is more focused and easier to read. It is now primarily focused on LtgA and Ape1 which has shortened the manuscript and improved the overall clarity.

> For example, the authors describe a number of proteins that bind the Δ30 protein, but not the wildtype protein, based on Figure 5. However, they go on to validate the binding of these proteins to the wildtype LtgA in Figure 6 not the mutant.

We thank the reviewer for pointing this out. We apologize if this was unclear however the purpose of this experiment was misunderstood because it was not communicated effectively in our original draft of our paper. Therefore, we will explain in more detail below:

In our manuscript we used the Label-free mass spectrometry developed by Mathias Mann (PMID: 25363814). We utilized two quantification strategies: (1) spectral counting and (2) spectrometric signal intensity to measure the protein expression.

All samples were analyzed by mass spectrometry separately using the same protocol. The proteins from each sample were identified using two strategies: 1) the protein expression from each sample is estimated using the number of MS/MS spectra identifying peptide of the protein and 2) the intensity of the corresponding MS spectrum features of the protein. Our output is the list of detected proteins and the absolute or relative abundance of the proteins across all samples for each experimental run, which was done in triplicates. I would like to emphasize that the mass spectrometry can only identify enriched peptides in one sample versus another. It does not tell you whether proteins are absolutely interacting directly or whether all peptides belonging to every single protein was identified, however it can be utilized to define the molecular environment of the protein of interest. For example, in both the wild-type and the delta helix strain PBP1a, LtgE, LtgD were identified but they were more enriched in the delta helix strain. In contrast, Ape1 peptides were not identified by mass spec in either strain which could be because of the abundance of Ape1 in the bacteria or some other technical issue.

Finally, we realize that the mass spectrometry and validation experiments of the LtgA interactome broadens the story and therefore based on suggestions from reviewer 3 we have refocused the manuscripts on LtgA and Ape1. The proteomic experiments have been moved to the supplementary and its limitation and precise utility discussed briefly in the main text. We apologize again for this confusion.

> They also claim that the Δ30 strain was cleared faster in mice, but they don\'t account for the slower growth rate of this crippled strain.

We apologize there was no detail explanation in the text. The Discussion has been modified. It now reads:

"Finally, to understand what role a defective LtgA that interferes with the normal function of the PG machinery plays in the pathogenesis of *N. meningitidis* we used a mouse infection model and showed Δ*ltgA^ltgA^*^Δ30^ strain of type *N. meningitidis* was cleared from the blood at a significantly faster rate than the wild-type, Δ*ltgA^ltgA^* or Δ*ltgA* strains. \[...\] Additionally, the helix deleted strain is hyperacetyaled and it is known that modification of the PG makes the cell wall more susceptible to complement-mediated lysis (Zarantonelli et al., 2013; Rosain et al., 2017), and PG modification is also associated with a decreased inflammatory response (Taguchi et al.,2018)."

> There are many other problems with the work that needs to be ironed out before this could be considered for publication.

We thank the reviewer for your critic. We addressed all the problems that were pointed out. The study was thorough, and comprehensive as well as cross-disciplined and while the presentation was unclear the experiments were executed with the utmost rigor in mind. As mentioned above we have focused the manuscript on LtgA and Ape1 which improved its clarity, focus and message.

> Reviewer \#3:
>
> \[...\]
>
> From the results of these experiments the authors conclude that LtgA mediates the function of a hub of PG glycan strand modifying enzymes, orchestrates cell division, cell wall integrity, and contributes to pathogenicity. Although there are several interesting aspects to this study, most of these stated conclusions are not justified by the data. I believe the authors should carefully reconsider their interpretation of the results and consider changing the focus of the manuscript to the Ape1-LtgA connection.

We agree with the reviewer that such a statement would be too preliminary, and we revised our conclusion: Please see below:

"We devised a multidisciplinary approach using structural biology to show that it is possible to target a 'hot spot' on an LT in order to affect bacterial growth, cell division, and cell membrane integrity, which resulted in lethal consequences for the bacteria during host infection. \[...\] A small molecule binding to alpha helix 30 could interfere with growth and simultaneously promote bacterial clearance, mimicking the enhanced clearance of the *ltgA^ltgA^*^Δ30^ mutant in a murine infection model".

> My major concerns are as follows:
>
> 1\) The observation that deletion of ltgA has no phenotype but that LtgA^Δ30^ expression is detrimental to growth indicates that a defective LtgA is worse than not having it at all. One cannot conclude from this observation that LtgA orchestrates cell division, cell wall integrity, or the function of an important enzymatic complex. If this were true, then the loss of ltgA function would result in division and cell wall defects. The more likely explanation of the results is that the catalytically defective LtgA^Δ30^ binds glycans and/or components of the PG biogenesis machinery and somehow impairs their function. Thus, the finding that LtgA^Δ30^ expression is detrimental provides a clue to LtgA function, but more information about the mechanism behind the dominant-negative phenotype is needed to make strong statements/conclusions about LtgA\'s role in the cell. At present, it is hard to tell whether or not the detrimental effects of LtgA^Δ30^ production has anything to do with its normal function, especially since it is expressed at about 3-5x greater concentration than the native enzyme in the reported experiments.

We thank the reviewer for this observation. We have changed the sentence in the Abstract to read:

"Here we show, that the active site of LtgA can be genetically modified to, affect the integrity of the cell wall, cell division, cell separation, and can impair the fitness of the human pathogen *Neisseria meningitidis* during infection."

We apologize if this was unclear however, LtgA^Δ30^ is produced relative to the wild type or the complemented strains at roughly 2 times greater amounts. Please see the exact quantification in Figure 2B and C. However, we agree and appreciate your point about the precision of the statement.

> 2\) I think it is important to know whether an active site point mutant of LtgA has a similar phenotype to LtgA^Δ30^. This will help determine whether LtgA^Δ30^ is special in some way, or if any catalytically defective enzyme will cause similar effects on cell division etc.

This is a very interesting point, however the mutant we created is defective in substrate binding and therefore could affect the ability of the LtgA^Δ30^ mutant catalyze efficiently the PG. However, this would be a part of a future more extensive exploration.

*3) The observation that LtgA interacts with PBP1a and LtgE* in vitro *is interesting. However, none of the results indicate that these interactions have a functional consequence in cells or on the enzymes* in vitro*. Thus, the conclusion that LtgA mediates the function of a hub of PG glycan strand modifying enzymes is not an appropriate one to make without further studies.*

The reviewer is correct. As pointed out above in the revised version we have removed this statement from the manuscript. Additionally, primarily based on your suggestion we have further refocused the paper on Ape1 and LtgA.

*Given that LtgA^Δ30^ expression affects PG acetylation in cells and LtgA promotes the activity of the deacetylase Ape1* in vitro*, there is a much more convincing functional connection between these enzymes. I would therefore recommend rewriting the paper to focus on the dominant negative phenotype of LtgA^Δ30^ and potentially other catalytically defective LtgA variants and how this uncovered a connection with Ape1 function.*

We thank the reviewer for this very important insight, and we have revised the manuscript to focus on these two main players Ape1 and LtgA.

*4) There is a disconnect between the co-immunoprecipitation/proteomic results and the* in vitro *SEC experiments. The co-IP data indicate that only LtgA^Δ30^ associates with PBP1a and other proteins, yet the SEC experiments are performed with LtgA (wild type). If the LtgA (wild type) is capable of interacting with these proteins, why did they not show up as hits in the proteomic analysis? Does LtgA^Δ30^ have a greater affinity for the interaction partners identified? This discrepancy raises concerns about the validity and reproducibility of the proteomic experiments.*

We thank the reviewer for pointing this out. We apologize if this was unclear however, since the purpose of this experiment was largely misunderstood, because it was not communicated effectively in our original draft of our paper. We will explain below:

In our manuscript we used the Label-free mass spectrometry developed by Mathias Mann (PMID: 25363814). We utilized two quantification strategies: (1) spectral counting and (2) spectrometric signal intensity to measure the protein expression. All samples were analyzed by mass spectrometry separately using the same protocol. The proteins from each sample were identified using two strategies: 1) the protein expression from each sample is estimated using the number of MS/MS spectra identifying peptide of the protein and 2) the intensity of the corresponding MS spectrum features of the protein. Our output is the list of detected proteins and the absolute or relative abundance of the proteins across all samples for each experimental run, which was done in triplicates. I would like to emphasize that the mass spectrometry can only identify enriched peptides in one sample versus another. It does not tell you whether proteins are absolutely interacting directly or whether all peptides belonging to every single protein was identified, however it can be utilized to define the molecular environment of the protein of interest. For example, in both the wild-type and the delta helix strain PBP1a, LtgE, LtgD were identified but they were more enriched in the delta helix strain. In contrast, Ape1 peptides were not identified by mass spec in either strain which could be because of the abundance of Ape1 in the bacteria or some other technical issue.

We acknowledge that the Mass spec and validation experiments of the LtgA interactome broadens the story and therefore based on your suggestions we have further refocused the manuscripts on LtgA and Ape1. The proteomic experiments have been moved to the supplementary and its limitation and precise utility discussed briefly in the main text.

\[Editors' note: what follows is the authors' response to the second round of review.\]

> Major issues requiring new experimentation:
>
> 1). The focus on the LtgA-Ape1 connection in the revised manuscript represents a major step in the right direction. However, with this renewed focus, it becomes important to provide some data that helps explain why Ape1 activity appears to be negatively impacted by expression of the LtgA^Δ30^ mutant. At a minimum, Ape1 levels should be assessed by western blot to determine whether or not it is stably expressed in these cells.

We thank the reviewer for this important insight. Ape1 is produced comparatively across each strain. Please see Figure 4---figure supplement 2.

*2) Additional support for the model that Ape1 is activated by LtgA* in vivo *should also be provided by examining whether or not Ape1 depletion results in a morphological defect that resembles that induced by the LtgA^Δ30^ mutant.*

We thank the reviewers for this suggestion. In our previous study we did note that a knockout of Ape1 resulted in the increased cell size of *Neissera meningitidis (*Veyrier et al. 2013). Here we examine the *Δape1* strain for morphological defects using SEM or labeling the cell wall with FM-64. While there were no pronounced differences in the division and separation, we did find significant cell shape abnormalities and lysed bacteria i.e. irregular cell surfaces, high molecular weight blebs, asymmetrical diplococci, and lysed bacteria Please see Figure 3---figure supplement 2.

> 3\) Testing whether or not expression of a catalytically defective LtgA mutant induces the same phenotype as the LtgA^Δ30^ mutant is an important experiment. It will indicate whether or not there is something special about the LtgA^Δ30^ mutant or if any catalytic defect will cause the observed effects. This experiment is not a difficult one, and given its importance, is not beyond the scope of the current manuscript or a subject for further study.

We thank the reviewer for the suggestion. A mutant of the catalytic residue did not result in any observable phenotype. Please see Figure 3---figure supplement 2.

> 4\) The title of the manuscript is too vague and does not convey any useful information to a potential reader. Consider something sharper and more on-point such as, \"A catalytically defective variant of a lytic transglycosylase disrupts cell morphogenesis by interfering with peptidoglycan deacetylation in Neisseria meningitidis\". Or something similar to this effect.

We loved your suggestion. However, it was too long based on the character limit from eLife. So we revised it to: "A defective lytic transglycosylase disrupts cell morphogenesis by hindering peptidoglycan de-O-acetylation in meningococcus."
